PharmTech Drug Digest 11.20
News|Articles|July 22, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-08-03-2016
  • Volume 11
  • Issue 8

Recipharm Expands Blow-Fill-Seal Capacity at France Facility

The company will invest €18 million in its Kaysersberg facility to expand blow-fill-seal capacity.

On July 5, 2016, Recipharm announced that the company will invest €18 million (approximately $19.73) to expand blow-fill-seal (BFS) capacity at its site in Kaysersberg, France. The investment will include the introduction of a BFS high-speed filling and packaging line, Recipharm said in a press announcement. Recihparm’s Kaysersberg site is a sterile facility specializing in BFS technology for sterile liquids.

Recipharm says it will also prepare to add three additional filling lines to the facility in upcoming years, increasing the company’s BFS capacity by 50%. Yves Buelens, general manager of the Kaysersberg site, said the company is experiencing increased demand for BFS services. “We are experiencing increased demand for our blow-fill-seal services from markets including the United States, Turkey, Australia, and Canada, and the new filling line will help us to meet this growing need,” Buelens noted in a press announcement.

Source: Recipharm

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.